Caffeine and its metabolites as potential contributors to Parkinson’s disease resistance

Takeaway

  • Concentrations of caffeine, its demethylation metabolites, and trigonelline were significantly lower in subjects with Parkinson’s disease (PD) with leucine-rich repeat kinase 2 (LRRK2) mutations (LRRK2+) than in unaffected controls (UC) and those without the mutations; these may be markers of PD resistance.

Why this matters

    The LRRK2 gene mutation is considered causative of PD but expresses incomplete penetration; identifying environmental factors that modulate its expression or effects on PD pathophysiology will potentially aid in PD prevention or mitigation.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.